Gilead's emvistegrast eliminates symptoms in ulcerative colitis Phase 2 trial
Gilead Sciences reported mid-stage study results showing its oral α4β7 inhibitor emvistegrast eliminated symptoms in patients with ulcerative colitis, with remission rates exceeding those of Entyvio. The company plans to begin late-stage trials in 2027.
